The presence of asymmetric septal hypertrophy and systolic anterior movement (SAM) of the anterior leaflet of the mitral valve on echocardiogram or cMR strongly suggests the diagnosis of hypertrophic obstructive cardiomyopathy (HOCM) in this patient. This is further supported by his symptoms of exertional dyspnoea and family history of sudden cardiac death, possibly related to HOCM. The observation of SAM on echocardiogram is a common finding in patients with HOCM.

Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects muscle tissue and is inherited in an autosomal dominant manner. It is caused by mutations in genes that encode contractile proteins, with the most common defects involving the β-myosin heavy chain protein or myosin-binding protein C. HOCM is characterized by left ventricle hypertrophy, which leads to decreased compliance and cardiac output, resulting in predominantly diastolic dysfunction. Biopsy findings show myofibrillar hypertrophy with disorganized myocytes and fibrosis. HOCM is often asymptomatic, but exertional dyspnea, angina, syncope, and sudden death can occur. Jerky pulse, systolic murmurs, and double apex beat are also common features. HOCM is associated with Friedreich’s ataxia and Wolff-Parkinson White. ECG findings include left ventricular hypertrophy, non-specific ST segment and T-wave abnormalities, and deep Q waves. Atrial fibrillation may occasionally be seen.

The superior parathyroid glands are formed from the fourth pharyngeal pouch during embryonic development. The pharyngeal pouches develop between the branchial arches, with the first pouch located between the first and second arches. There are four pairs of pouches, with the fifth pouch being either absent or very small. A helpful mnemonic to remember the derivatives of the four pharyngeal pouches is 1A, 2P, 3 TIP, 4 SUB. This stands for the auditory tube, middle ear cavity, and mastoid antrum for the first pouch; the crypts of the palatine tonsil for the second pouch; the thymus and inferior parathyroid gland for the third pouch; and the superior parathyroid gland and ultimobranchial body for the fourth pouch.

Anatomy and Development of the Parathyroid Glands

The parathyroid glands are four small glands located posterior to the thyroid gland within the pretracheal fascia. They develop from the third and fourth pharyngeal pouches, with those derived from the fourth pouch located more superiorly and associated with the thyroid gland, while those from the third pouch lie more inferiorly and may become associated with the thymus.

The blood supply to the parathyroid glands is derived from the inferior and superior thyroid arteries, with a rich anastomosis between the two vessels. Venous drainage is into the thyroid veins. The parathyroid glands are surrounded by various structures, with the common carotid laterally, the recurrent laryngeal nerve and trachea medially, and the thyroid anteriorly. Understanding the anatomy and development of the parathyroid glands is important for their proper identification and preservation during surgical procedures.

The Role of Endothelial Damage in Atherosclerosis

The development of atherosclerosis requires endothelial damage to occur. Hypertension is the most likely risk factor to cause this damage, as it alters blood flow and increases shearing forces on the endothelium. Once damage occurs, pro-inflammatory mediators are released, leading to leucocyte adhesion and increased permeability in the vessel wall. Endothelial damage is particularly atherogenic due to the release of platelet-derived growth factor and thrombin, which stimulate platelet adhesion and activate the clotting cascade.

Diabetes mellitus, hypercholesterolaemia, and obesity increase LDL levels, which infiltrate the arterial intima and contribute to the formation of atheromatous plaques. However, before LDLs can infiltrate the vessel wall, they must bind to endothelial adhesion molecules, which are released after endothelial damage occurs. Therefore, hypertension-induced endothelial damage is required for the initial development of atherosclerosis.

Smoking is also a risk factor for atherosclerosis, but the mechanism is not well understood. It is believed that free radicals and aromatic compounds in tobacco smoke inhibit the production of nitric oxide, leading to endothelial damage. Overall, the role of endothelial damage in atherosclerosis can help identify effective prevention and treatment strategies.

For patients with recurrent venous thromboembolic disease, an inferior vena cava filter may be considered. This is particularly relevant for patients with cancer who have experienced multiple DVTs despite being fully anticoagulated. Before considering an inferior vena cava filter, alternative treatments such as increasing the target INR to 3-4 for long-term high-intensity oral anticoagulant therapy or switching to LMWH should be considered. This recommendation is in line with NICE guidelines on the diagnosis, management, and thrombophilia testing of venous thromboembolic diseases. Prescribing apixaban, increasing the dose of dabigatran off-license, or prescribing Thrombo-Embolic Deterrent (TED) stockings are not appropriate solutions for this patient. Similarly, initiating end-of-life drugs and preparing the family is not indicated based on the clinical description provided.

Management of Pulmonary Embolism

Pulmonary embolism (PE) is a serious condition that requires prompt management. The National Institute for Health and Care Excellence (NICE) updated their guidelines on the management of venous thromboembolism (VTE) in 2020, with some key changes. One of the significant changes is the recommendation to use direct oral anticoagulants (DOACs) as the first-line treatment for most people with VTE, including those with active cancer. Another change is the increasing use of outpatient treatment for low-risk PE patients, determined by a validated risk stratification tool.

Anticoagulant therapy is the cornerstone of VTE management. The guidelines recommend using apixaban or rivaroxaban as the first-line treatment for PE, followed by LMWH, dabigatran, edoxaban, or a vitamin K antagonist (VKA) if necessary. For patients with active cancer, DOACs are now recommended instead of LMWH. The length of anticoagulation depends on whether the VTE was provoked or unprovoked, with treatment typically lasting for at least three months. Patients with unprovoked VTE may continue treatment for up to six months, depending on their risk of recurrence and bleeding.

In cases of haemodynamic instability, thrombolysis is recommended as the first-line treatment for massive PE with circulatory failure. Other invasive approaches may also be considered where appropriate facilities exist. Patients who have repeat pulmonary embolisms, despite adequate anticoagulation, may be considered for inferior vena cava (IVC) filters. However, the evidence base for IVC filter use is weak, and further studies are needed.

Troponin and Its Significance in Cardiac Health

Troponin is an enzyme that is specific to the heart and is used to detect injury to the heart muscle. It is commonly measured in patients who present with chest pain that may be related to heart problems. Elevated levels of troponin can indicate a heart attack or other acute coronary syndromes. However, it is important to note that troponin levels may also be slightly elevated in other conditions such as renal failure, cardiomyopathy, myocarditis, and large pulmonary embolism.

Troponin is a crucial marker in the diagnosis and management of cardiac conditions. It is a reliable indicator of heart muscle damage and can help healthcare professionals determine the best course of treatment for their patients. Additionally, troponin levels can provide prognostic information, allowing doctors to predict the likelihood of future cardiac events. It is important for individuals to understand the significance of troponin in their cardiac health and to seek medical attention if they experience any symptoms of heart problems.

The leading cause of heart failure in the western world is ischaemic heart disease, followed by high blood pressure, cardiomyopathies, arrhythmias, and heart valve issues. While COPD can be linked to cor pulmonale, which is a type of right heart failure, it is still not as prevalent as ischaemic heart disease as a cause. This information is based on a population-based study titled Incidence and Aetiology of Heart Failure published in the European Heart Journal in 1999.

Diagnosis of Chronic Heart Failure

Chronic heart failure is a serious condition that requires prompt diagnosis and management. In 2018, the National Institute for Health and Care Excellence (NICE) updated its guidelines on the diagnosis and management of chronic heart failure. According to the new guidelines, all patients should undergo an N-terminal pro-B-type natriuretic peptide (NT‑proBNP) blood test as the first-line investigation, regardless of whether they have previously had a myocardial infarction or not.

Interpreting the NT-proBNP test is crucial in determining the severity of the condition. If the levels are high, specialist assessment, including transthoracic echocardiography, should be arranged within two weeks. If the levels are raised, specialist assessment, including echocardiogram, should be arranged within six weeks.

BNP is a hormone produced mainly by the left ventricular myocardium in response to strain. Very high levels of BNP are associated with a poor prognosis. The table above shows the different levels of BNP and NTproBNP and their corresponding interpretations.

It is important to note that certain factors can alter the BNP level. For instance, left ventricular hypertrophy, ischaemia, tachycardia, and right ventricular overload can increase BNP levels, while diuretics, ACE inhibitors, beta-blockers, angiotensin 2 receptor blockers, and aldosterone antagonists can decrease BNP levels. Therefore, it is crucial to consider these factors when interpreting the NT-proBNP test.

The patient’s symptoms and physical exam suggest the presence of aortic stenosis. This is indicated by the ejection systolic murmur, slow-rising pulse, and progressive heart failure symptoms. The fourth heart sound (S4) is also present, which occurs when the left atrium contracts forcefully to compensate for a stiff ventricle. In aortic stenosis, the left ventricle is hypertrophied due to the narrowed valve, leading to the S4 sound.

While hepatomegaly is more commonly associated with right heart valvular disease, it is not entirely ruled out in this case. However, the patient’s history is more consistent with aortic stenosis.

Malar flush, a pink flushed appearance across the cheeks, is typically seen in mitral stenosis due to hypercarbia causing arteriole vasodilation.

Pistol shot femoral pulses, a sound heard during systole when auscultating the femoral artery, is a finding associated with aortic regurgitation and not present in this case.

Heart sounds are the sounds produced by the heart during its normal functioning. The first heart sound (S1) is caused by the closure of the mitral and tricuspid valves, while the second heart sound (S2) is due to the closure of the aortic and pulmonary valves. The intensity of these sounds can vary depending on the condition of the valves and the heart. The third heart sound (S3) is caused by the diastolic filling of the ventricle and is considered normal in young individuals. However, it may indicate left ventricular failure, constrictive pericarditis, or mitral regurgitation in older individuals. The fourth heart sound (S4) may be heard in conditions such as aortic stenosis, HOCM, and hypertension, and is caused by atrial contraction against a stiff ventricle. The different valves can be best heard at specific sites on the chest wall, such as the left second intercostal space for the pulmonary valve and the right second intercostal space for the aortic valve.

ADP receptor inhibitors, such as clopidogrel, prasugrel, ticagrelor, and ticlopidine, work by inhibiting the P2Y12 receptor, which leads to sustained platelet aggregation and stabilization of the platelet plaque. Clinical trials have shown that prasugrel and ticagrelor are more effective than clopidogrel in reducing short- and long-term ischemic events in high-risk patients with acute coronary syndrome or undergoing percutaneous coronary intervention. However, ticagrelor may cause dyspnea due to impaired clearance of adenosine, and there are drug interactions and contraindications to consider for each medication. NICE guidelines recommend dual antiplatelet treatment with aspirin and ticagrelor for 12 months as a secondary prevention strategy for ACS.

The fracture segment can be pulled backwards by the contraction of the gastrocnemius heads, which may result in damage or compression of the popliteal artery that runs adjacent to the bone.

Anatomy of the Popliteal Fossa

The popliteal fossa is a diamond-shaped space located at the back of the knee joint. It is bound by various muscles and ligaments, including the biceps femoris, semimembranosus, semitendinosus, and gastrocnemius. The floor of the popliteal fossa is formed by the popliteal surface of the femur, posterior ligament of the knee joint, and popliteus muscle, while the roof is made up of superficial and deep fascia.

The popliteal fossa contains several important structures, including the popliteal artery and vein, small saphenous vein, common peroneal nerve, tibial nerve, posterior cutaneous nerve of the thigh, genicular branch of the obturator nerve, and lymph nodes. These structures are crucial for the proper functioning of the lower leg and foot.

Understanding the anatomy of the popliteal fossa is important for healthcare professionals, as it can help in the diagnosis and treatment of various conditions affecting the knee joint and surrounding structures.

The patient’s symptoms and elevated CK levels suggest that she may have rhabdomyolysis, which is a known risk associated with taking statins while also taking amiodarone. It is likely that her cardiologist prescribed amiodarone. To reduce her risk of statin-induced rhabdomyolysis, her atorvastatin dosage should be lowered.

It is important to note that digoxin and beta-blockers do not increase the risk of statin-induced rhabdomyolysis, and there is no association between laxatives and this condition.

Amiodarone is a medication used to treat various types of abnormal heart rhythms. It works by blocking potassium channels, which prolongs the action potential and helps to regulate the heartbeat. However, it also has other effects, such as blocking sodium channels. Amiodarone has a very long half-life, which means that loading doses are often necessary. It should ideally be given into central veins to avoid thrombophlebitis. Amiodarone can cause proarrhythmic effects due to lengthening of the QT interval and can interact with other drugs commonly used at the same time. Long-term use of amiodarone can lead to various adverse effects, including thyroid dysfunction, corneal deposits, pulmonary fibrosis/pneumonitis, liver fibrosis/hepatitis, peripheral neuropathy, myopathy, photosensitivity, a ‘slate-grey’ appearance, thrombophlebitis, injection site reactions, and bradycardia. Patients taking amiodarone should be monitored regularly with tests such as TFT, LFT, U&E, and CXR.